Literature DB >> 16043269

Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants.

Jennifer A Slyker1, Barbara L Lohman, Dorothy A Mbori-Ngacha, Marie Reilly, Edmund G-T Wee, Tao Dong, Andrew J McMichael, Sarah L Rowland-Jones, Tomas Hanke, Grace John-Stewart.   

Abstract

Recombinant modified vaccinia virus Ankara expressing HIV-1 antigens (MVA.HIVA) was used in ELISpot assays to monitor HIV-1-specific T cell responses in infants. Responses to MVA.HIVA and HIV-1 peptides were examined in 13 infected and 81 exposed uninfected infants in Nairobi, Kenya. Responses to MVA.HIVA (38%) and peptide stimulation (38%) were similar in frequency (p=1.0) and magnitude (mean 176 versus 385 HIVSFU/10(6), p=0.96) in HIV-1 infected infants. In exposed uninfected infants, MVA.HIVA detected more positive responses and higher magnitude responses as compared to peptide. MVA.HIVA ELISpot is a sensitive method for quantification of HIV-1-specific CD8+ T cell responses in HIV-1 exposed infants. These results demonstrate the relevance of HIV-1 clade A consensus-derived immunogen HIVA for the viruses currently circulating in Nairobi.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16043269      PMCID： PMC3382083          DOI： 10.1016/j.vaccine.2005.01.145

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  43 in total

1.  Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry.

Authors:  W J Moretto; L A Drohan; D F Nixon
Journal:  AIDS       Date:  2000-11-10       Impact factor: 4.177

2.  CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition.

Authors:  G Ferrari; W Neal; A Jones; N Olender; J Ottinger; R Ha; M J McElrath; P Goepfert; K J Weinhold
Journal:  Immunol Lett       Date:  2001-11-01       Impact factor: 3.685

3.  Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya.

Authors:  T Hanke; A J McMichael
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

4.  Differences between T cell epitopes recognized after immunization and after infection.

Authors:  Thorsten U Vogel; Helen Horton; Deborah H Fuller; Donald K Carter; Kathy Vielhuber; David H O'Connor; Tim Shipley; Jim Fuller; Gerd Sutter; Volker Erfle; Nancy Wilson; Louis J Picker; David I Watkins
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

5.  HIV-1 replication increases HIV-specific CD4+ T cell frequencies but limits proliferative capacity in chronically infected children.

Authors:  Zachary A Scott; Coreen M Beaumier; Mark Sharkey; Mario Stevenson; Katherine Luzuriaga
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

6.  A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques.

Authors:  Edmund G-T Wee; Sandip Patel; Andrew J McMichael; Tomáš Hanke
Journal:  J Gen Virol       Date:  2002-01       Impact factor: 3.891

7.  CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects.

Authors:  R Kaul; T Dong; F A Plummer; J Kimani; T Rostron; P Kiama; E Njagi; E Irungu; B Farah; J Oyugi; R Chakraborty; K S MacDonald; J J Bwayo; A McMichael; S L Rowland-Jones
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

8.  Interferon-gamma and interleukin-10 production among HIV-1-infected and uninfected infants of HIV-1-infected mothers.

Authors:  L Kuhn; A Coutsoudis; D Moodley; N Mngqundaniso; D Trabattoni; G M Shearer; M Clerici; H M Coovadia
Journal:  Pediatr Res       Date:  2001-09       Impact factor: 3.756

9.  Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines.

Authors:  Matilu Mwau; Andrew J McMichael; Tomás Hanke
Journal:  AIDS Res Hum Retroviruses       Date:  2002-06-10       Impact factor: 2.205

10.  A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.

Authors:  Matilu Mwau; Inese Cebere; Julian Sutton; Priscilla Chikoti; Nicola Winstone; Edmund G-T Wee; Tara Beattie; Yun-Hsiang Chen; Lucy Dorrell; Helen McShane; Claudia Schmidt; Mary Brooks; Sandip Patel; Joanna Roberts; Christopher Conlon; Sarah L Rowland-Jones; Job J Bwayo; Andrew J McMichael; Tomáš Hanke
Journal:  J Gen Virol       Date:  2004-04       Impact factor: 3.891
View more
  7 in total

1.  Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.

Authors:  Maximillian Rosario; Richard Hopkins; John Fulkerson; Nicola Borthwick; Máire F Quigley; Joan Joseph; Daniel C Douek; Hui Yee Greenaway; Vanessa Venturi; Emma Gostick; David A Price; Gerald W Both; Jerald C Sadoff; Tomás Hanke
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

Review 2.  The challenge of assessing infant vaccine responses in resource-poor settings.

Authors:  Katie L Flanagan; Sarah Burl; Barbara L Lohman-Payne; Magdalena Plebanski
Journal:  Expert Rev Vaccines       Date:  2010-06       Impact factor: 5.217

3.  HV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission.

Authors:  Grace C John-Stewart; Dorothy Mbori-Ngacha; Barbara Lohman Payne; Carey Farquhar; Barbra A Richardson; Sandra Emery; Phelgona Otieno; Elizabeth Obimbo; Tao Dong; Jennifer Slyker; Ruth Nduati; Julie Overbaugh; Sarah Rowland-Jones
Journal:  J Infect Dis       Date:  2009-03-15       Impact factor: 5.226

4.  Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18.

Authors:  Laila Darwich; Gemma Coma; Ruth Peña; Rocio Bellido; Ester J J Blanco; José A Este; Francesc E Borras; Bonaventura Clotet; Lidia Ruiz; Antoni Rosell; Felipe Andreo; R Michael E Parkhouse; Margarita Bofill
Journal:  Immunology       Date:  2008-08-28       Impact factor: 7.397

5.  HIV-1 Vaccine Trials: Evolving Concepts and Designs.

Authors:  Missa P Sanou; Anne S De Groot; Michael Murphey-Corb; Jay A Levy; Janet K Yamamoto
Journal:  Open AIDS J       Date:  2012-11-30

6.  Design and pre-clinical evaluation of a universal HIV-1 vaccine.

Authors:  Sven Létourneau; Eung-Jun Im; Tumelo Mashishi; Choechoe Brereton; Anne Bridgeman; Hongbing Yang; Lucy Dorrell; Tao Dong; Bette Korber; Andrew J McMichael; Tomás Hanke
Journal:  PLoS One       Date:  2007-10-03       Impact factor: 3.240

7.  Vaccine platform for prevention of tuberculosis and mother-to-child transmission of human immunodeficiency virus type 1 through breastfeeding.

Authors:  Eung-Jun Im; Narcís Saubi; Goretti Virgili; Clare Sander; Denise Teoh; Jose M Gatell; Helen McShane; Joan Joseph; Tomás Hanke
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.